Q-Line Biotech Limited (NSE:QLINE)

Q-Line Biotech Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	764.37	470.26	299.56	900.19	465.37
Short-Term Investments	-	-	-	-	75.72
Cash & Short-Term Investments	764.37	470.26	299.56	900.19	541.1
Cash Growth	62.54%	56.98%	-66.72%	66.36%	1861.13%
Accounts Receivable	1,258	826.03	264.44	330.58	430.35
Other Receivables	-	120	-	-	19.89
Receivables	1,624	946.17	264.44	330.58	450.25
Inventory	949.6	902.13	1,052	435.94	376.26
Prepaid Expenses	-	5.2	5.11	1.68	1.93
Other Current Assets	102.63	322.62	363.8	92.71	391.95
Total Current Assets	3,441	2,646	1,985	1,761	1,761
Property, Plant & Equipment	1,340	1,125	740.43	344.6	94
Long-Term Investments	166.74	0	285.11	157.04	-
Goodwill	2.69	2.69	-	-	-
Other Intangible Assets	266.4	46.34	12.59	0.81	-
Long-Term Deferred Tax Assets	10.63	9.81	5.78	7.07	1.47
Long-Term Deferred Charges	-	187.83	37.92	-	-
Other Long-Term Assets	305.35	532.66	315.39	235.59	12.51
Total Assets	5,587	4,555	3,392	2,516	1,920

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	520.43	556.25	592.38	397.06	346.61
Accrued Expenses	-	195.91	98.36	53.28	16.46
Short-Term Debt	1,293	554.61	504.02	541.7	334.18
Current Portion of Long-Term Debt	-	270.77	114.15	51.72	-
Current Portion of Leases	-	13.45	-	-	-
Current Income Taxes Payable	-	141.22	23.55	27.87	62.95
Current Unearned Revenue	-	36.98	6.72	5.03	-
Other Current Liabilities	285.83	22.25	63.6	4.85	39.42
Total Current Liabilities	2,099	1,791	1,403	1,081	799.61
Long-Term Debt	961.92	824.12	350.93	143.07	100.13
Pension & Post-Retirement Benefits	43.93	26.18	18.58	16.58	-
Other Long-Term Liabilities	19.92	13.68	2.03	1	0
Total Liabilities	3,125	2,655	1,774	1,242	899.75

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	162.75	15.75	15.75	15.75	15.75
Additional Paid-In Capital	-	13.01	13.01	13.01	-
Retained Earnings	-	1,871	1,589	1,245	-
Comprehensive Income & Other	2,299	-	-	-	1,004
Shareholders' Equity	2,462	1,899	1,618	1,274	1,020
Total Liabilities & Equity	5,587	4,555	3,392	2,516	1,920

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	2,255	1,663	969.1	736.48	434.32
Net Cash (Debt)	-1,490	-1,193	-669.54	163.71	106.78
Net Cash Growth	-	-	-	53.31%	-
Net Cash Per Share	-93.06	-75.73	-42.51	10.39	7.12
Filing Date Shares Outstanding	14.83	16.27	15.75	15.75	15.75
Total Common Shares Outstanding	14.83	16.27	15.75	15.75	15.75
Working Capital	1,341	854.95	582.54	679.61	961.86
Book Value Per Share	166.06	116.71	102.74	80.87	64.76
Tangible Book Value	2,193	1,850	1,606	1,273	1,020
Tangible Book Value Per Share	147.91	113.70	101.94	80.82	64.76
Land	-	203.51	201.41	123.74	-
Buildings	-	153.08	148.94	32.3	-
Machinery	-	369.65	323.98	158.44	-
Construction In Progress	-	590.31	191.72	117.37	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 24, 2026

Data Sources Report a data error